devseek (Sequence(Analysis(Panel(for(Neurodevelopmental(Disorders

Targeted Genes and Methodology Details for Epilepsy/Seizure Genetic Panels

Targeted s and Methodology Details for Epilepsy/Seizure tic Panels Reference transcripts based on build GRCh37 (hg19) interrogated by Epilepsy/Seizure tic Panels Epilepsy Expanded Panel Epilepsy Expanded

'Translating massively parallel sequencing into clinical diagnostics.

'Translating massively parallel sequencing into clinical diagnostics. SA Pathology at the Women s and and The University of Adelaide Adelaide, Australia MPS is revolutionising genetics & biology - >100

The Japanese collaborated study of Fragile X syndrome and its related disorders

The Japanese collaborated study of Fragile X syndrome and its related disorders Yuji Nakayama, PhD Research Center for Bioscience and Technology, Tottori University, Japan TOTTORI Tsukuba Kyoto TOKYO Okayama

PITTSBURGH CYTOGENETICS LABORATORY

PITTSBURGH CYTOGENETICS LABORATORY GENES COVERED BY X-HR AND SYNDROMES DETECTED BY X-HR # GENES LOCI DISORDERS 1 ABCB7 Xq12-q13 Anemia, sideroblastic, with ataxia 2 ABCD1 Xq28 Adrenoleukodystrophy 3 ACSL4

ERN EpiCARE. A European Reference Network for Rare and Complex Epilepsies. Petr Marusic Motol University Hospital, Prague

ERN EpiCARE A European Reference Network for Rare and Complex Epilepsies Petr Marusic Motol University Hospital, Prague Disclosure I have no actual or potential conflict of interest in relation to this

Whole exome sequencing Gene package Autism version 2,

Whole Exome Sequencing Gene package Autism, version 2, 1 7 2017 Technical information After DNA was enriched using Agilent Sureselect Clinical Research Exome (CRE) Capture, samples were run on the Illumina

Whole exome sequencing Gene package Autism version 2.1,

Whole Exome Sequencing Gene package Autism, version 2.1, 22 11 2017 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired end sequenced on the Illumina

A European Reference Network for rare and complex epilepsies. J Helen Cross Coordinator

A European Reference Network for rare and complex epilepsies J Helen Cross Coordinator The epilepsies a group of rare diseases Early myoclonic encephalopathy PIGA, SETBP1, SIK1, SLC25A22 Dravet syndrome

Phone: Referring Provider: NPI #: Referring Laboratory (if different): Physician signature: Name: Name: Address: Address:

MOLECULAR (DNA) TEST REQUISITION FOR CHG LAB USE ONLY: Center for Human Genetics, Inc. Date received: Riverside Technology Center Pedigree #: 840 Memorial Drive, Suite 101 Family name: Cambridge, MA 02139

Phone: Address: Address: City State Zip Code City State Zip Code. Phone: Fax: Phone: Fax: Genetic Counselor:

MOLECULAR (DNA) TEST REQUISITION FOR CHG LAB USE ONLY: Center for Human Genetics, Inc. Date received: Riverside Technology Center Pedigree #: 840 Memorial Drive, Suite 101 Family name: Cambridge, MA 02139

Phone: Address: Address: City State Zip Code City State Zip Code. Phone: Fax: Phone: Fax: Genetic Counselor:

MOLECULAR (DNA) TEST REQUISITION FOR CHG LAB USE ONLY: Center for Human Genetics, Inc. Date received: Riverside Technology Center Pedigree #: 840 Memorial Drive, Suite 101 Family name: Cambridge, MA 02139

Role of Molecular Genetic Assessment for Autism in Clinical Setting

Role of Molecular Genetic Assessment for Autism in Clinical Setting Young Shin Kim, MD, MS, MPH, PhD Director STAR Center for ASD and NDDs Psychiatric Genetic Epidemiology Associate Professor Dept. of

Clinical Diagnosis of Mendelian Disorders Using a Comprehensive Gene-Targeted Panel Test for Next-Generation Sequencing

Yonago Acta medica 2016;59:118 125 Original Article Clinical Diagnosis of Mendelian Disorders Using a Comprehensive Gene-Targeted Panel Test for Next-Generation Sequencing Tetsuya Okazaki,* Megumi Murata,

The University of Chicago Genetic Services Laboratories

Aceruloplasminemia testing CP sequencing Aceruloplasminemia CP deletion/duplication Albinism testing Albinism Sequencing Panel (20 genes Albinism Deletion/Duplication Panel (20 genes Alstrom syndrome testing

Family Education and Support

Family Education and Support Key Topics First Aid Seizure Safety Sports Physical Activity Driving Familial Psychosocial Needs in Treating Pediatric Epilepsy Poll Question 1 Which of the following is not

Epilepsy. Genetic Test Submission Guide. 2. Samples. 1. Forms. 3. Ship RESULTS. impactgenetics.com

Epilepsy Genetic Test Submission Guide 1. Forms 2. Samples Form 1d: If applicable Form 1b: Requisition Form Form 1a: Informed Consent 3. Ship RESULTS Impact Genetics, Dynacare 4-1100 Bennett Rd. Bowmanville,

SUPPLEMENTARY INFORMATION

doi:10.1038/nature11011 Data generation, processing and identifying de novo mutations Data generation Exome capture and sequencing was performed at each site using similar methods. Genomic DNA (~3 ug)

DIAGNOSTICS THROUGH MICROARRAY POSTNATAL DIAGNOSIS

DIAGNOSTICS THROUGH MICROARRAY POSTNATAL DIAGNOSIS COMPANY PROFILE Microgenomics S.r.l. is a spin-off company of the University of Pavia founded by the research team of Molecular Cytogenetics of the Department

Next-generation sequencing using a pre-designed gene panel for the molecular diagnosis of congenital disorders in pediatric patients

Lim et al. Human Genomics (2015) 9:33 DOI 10.1186/s40246-015-0055-x PRIMARY RESEARCH Open Access Next-generation sequencing using a pre-designed gene panel for the molecular diagnosis of congenital disorders

Request for expedited Result

London Health Sciences Centre Molecular Genetics Laboratories Requisition for DNA Testing DACC002 REV 20170815 AUTHORIZED SIGNATURE IS REQUIRED INCOMPLETE REQUESTS WILL BE BANKED Molecular Genetics Laboratory

Division of Genomic Diagnostics GENOMIC DIAGNOSTICS TEST REQUISITION *For Cancer tests please use the Cancer Test Requisition.

Page 1 of 8 SHIP TO: Children s Hospital of Philadelphia, Genomic Diagnostics Laboratory, 3615 Civic Center Blvd., Abramson Research Center, 714, Philadelphia, PA 19104-4302 - Phone: (215) 590-4452 PATIENT

Quick Guide To Genetic Testing

Aceruloplasminemia testing CP sequencing 2101 81406 4 weeks $1,000 Aceruloplasminemia CP deletion/duplication 2102 81405 4 weeks $1,000 Albinism testing Albinism Sequencing ** 1101 81407 8 weeks $2,500

Quick Guide To Genetic Testing

Aceruloplasminemia testing CP sequencing 2101 81406 4 weeks $1,000 Aceruloplasminemia CP deletion/duplication 2102 81405 4 weeks $1,000 Albinism testing Albinism Sequencing Panel** 1101 81407 8 weeks $2,500

Requisition for DNA Testing. Reason for Referral: Patient Information: INCOMPLETE REQUESTS WILL BE BANKED. Test Requests: Sample Collection:

Reason for Referral: Diagnostic Testing: Affected Unaffected Carrier testing/known Family Mutation Name of index case in the family (include copy of report): Date of Birth: Relationship to this patient:

Genomic Service List

Document ID: MBG-C009 Effective Date: 10 Jan 018 Page: 1 of 5 WHOLE GENOME SEQUENCING Human Whole Genome Sequencing 1 HGG-15 Human Whole Genome Sequencing HGG-157 (FASTQ data only) WHOLE EXOME SEQUENCING

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:1.138/nature12912 Figure S1. Distribution of mutation rates and spectra across 4,742 tumor-normal (TN) pairs from 21 tumor types, as in Figure 1 from Lawrence et al. Nature

Name: Last First Date of Birth (mm/dd/yyyy): Gender: Male Female MRN: Ethnicity: Caucasian African-American Hispanic Asian Ashkenazi Jewish Other

Requisition Form 5841 South Maryland Avenue, Room G701/MC0077, Chicago, IL 60637 Toll Free: 888.824.3637 Local: 773.834.0555 Fax: 773.702.9130 ucgslabs@genetics.uchicago.edu dnatesting.uchicago.edu CLIA#:

Dr. Sarah Weckhuysen, MD, PhD. Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium

Dr. Sarah Weckhuysen, MD, PhD Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium Common Prevalence 4-8/1000 Life time incidence 3% Key symptom = seizures Nature Reviews

Reverse phenotyping: MCD Detection without clinical diagnosis. Diagnostic: NGS panels versus WES

Clinical Genetics Leading the way in genetic issues Reverse phenotyping: MCD Detection without clinical diagnosis Diagnostic: NGS panels versus WES Martina Wilke Laboratory Specialist Clinical Genetics

Get a more complete picture into your patient's pregnancy with PreSeek

PRENATAL Expecting a baby is an exciting and mysterious time. And it s natural for your patient to wonder if they have a healthy pregnancy. Introducing PreSeek, the most comprehensive, single gene, cell-free

SUPPLEMENTARY INFORMATION

Supplementary information S1 (table) Examples of genes associated with ASD and their main clinical phenotypes. Genes Observations Chromatin remodelling MECP2 Females with a mutation in the X-linked MECP2

Whole exome sequencing Gene package Epilepsy version 1,

Whole Exome Sequencing Gene package Epilepsy, version 1, 8 4 2015 Technical information After DNA was enriched using Agilent Sureselect Clinical Research Exome (CRE) Capture, samples were run on the Illumina

Leistungsverzeichnis

Leistungsverzeichnis SYNLAB MVZ Humangenetik Mannheim Genetische Beratung / Molekulargenetische Diagnostik / Molekulare Zytogenetik / Abstammungsgutachten und Vaterschaftstest www.zhma.de Akkreditiert

Nature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data.

Supplementary Figure 1 Depths and coverages in whole-exome and targeted deep sequencing data. Depth (top) and coverage (bottom) of whole-exome sequencing for 38 independent JPN cases (mean depth = 130)

Outline. Next-Generation Sequencing. The Application of Genomic Medicine in Clinical and Laboratory Practice

Outline The Application of Genomic Medicine in Clinical and Laboratory Practice Jerry Feldman, MD, PhD, FACMG Medical Director, Division of Laboratory Genetics and Molecular Pathology, Detroit Medical

REVIEW ARTICLE The Role of Neuronal Complexes in Human X-Linked Brain Diseases

REVIEW ARTICLE The Role of Neuronal Complexes in Human X-Linked Brain Diseases Frédéric Laumonnier, Peter C. Cuthbert, and Seth G. N. Grant Beyond finding individual genes that are involved in medical

I. New Syndromes and Localizations

Information posted on this page is intended to complement and update the Atlas of X-Linked Intellectual Disability Syndromes, Edition 2, by R.E. Stevenson, C.E. Schwartz, and R.C. Rogers (Oxford University

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our

Table S1: List of the 646 known pathogenic genes targeted in the present study and their associated mode of inheritance. ARID: autosomal-recessive

Table S1: List of the 646 known pathogenic genes targeted in the present study and their associated mode of inheritance. : autosomal-recessive intellectual disability; : autosomal-dominant intellectual

August 7, Dear Ms. Verma: RE: 2018 Preliminary Gapfill Payment Determinations for CY2019. Dear Ms. Verma:

ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August

A genome-wide linkage study of autism spectrum disorder and the broad autism. phenotype in extended pedigrees

A genome-wide linkage study of autism spectrum disorder and the broad autism phenotype in extended pedigrees Short title: Genome-wide linkage in autism extended pedigrees Marc Woodbury-Smith, Andrew D.

Precision Oncology: Experience at UW

Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT

A Targeted Next Generation Sequencing (tngs) Screening Assay for Menkes Disease and its Implications for Primary DNA-based Newborn Screening

A Targeted Next Generation Sequencing (tngs) Screening Assay for Menkes Disease and its Implications for Primary DNA-based Newborn Screening Richard B. Parad 1, Stephen G. Kaler 2, Evan Mauceli 4, Tanya

Test Information Sheet

Genetic Testing for Epilepsy: Childhood Epilepsy Panel Sequence Analysis and Exon-Level Deletion/Duplication Testing of 58 Genes Panel Gene List: SL, CACNA1A, CDKL5, CHD2, CHRNA2, CHRNA4, CHRNA7*, CHRNB2,

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations

Evaluation of CNV detection. from targeted next-generation panel sequencing data. in routine diagnostics

Evaluation of CNV detection from targeted next-generation panel sequencing data in routine diagnostics benet-pages@mgz-muenchen.de Anna Benet-Pagès Prague 07.11.2017 Structural variants in human disease

Rare Disease Research and the UK 100,000 Genome Project

Rare Disease Research and the UK 100,000 Genome Project Prof F Lucy Raymond MA DPhil FRCP Department of Medical Genetics University of Cambridge UK Flr24@cam.ac.uk Copenhagen October Precision Medicine

X-Linked Intellectual Disability (revised January 2019)

X-Linked Intellectual Disability (revised January 2019) Information posted on these pages are intended to complement and update the Atlas of X- Linked Intellectual Disability Syndromes, Edition 2, by Stevenson,

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center

Syddansk Universitet. Published in: npj Genomic Medicine. DOI: /s Publication date: 2018

Syddansk Universitet A 360 evaluation Oates, Stephanie; Tang, Shan; Rosch, Richard; Lear, Rosalie; Hughes, Elaine F.; Williams, Ruth E.; Larsen, Line H.G.; Hao, Qin; Dahl, Hans Atli; Møller, Rikke S; Pal,

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST

number of of condition inheritance

OMIM standard name of condition (please provide the conditions that the test is for which may NOT necssarily be the condition that is linked to the gene on OMIM) OMIM symbol of condition OMIM Mode number

Dr. Sarah Weckhuysen, MD, PhD. Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium

Dr. Sarah Weckhuysen, MD, PhD Neurogenetics Group, VIB-Department of Molecular Genetics University of Antwerp, Belgium Sarah Weckhuysen No relevant financial relationships with any commercial interests.

Integration of Next-Generation Sequencing into Epilepsy Clinical Care. Michelle Demos University of British Columbia BC Children s Hospital

Integration of Next-Generation Sequencing into Epilepsy Clinical Care Michelle Demos University of British Columbia BC Children s Hospital No Disclosures Learning Objectives To review: the impact of using

The Genetics of Alcoholism. Robert Hitzemann, Ph.D. Departments of Behavioral Neuroscience & Psychiatry Oregon Health & Science University

The Genetics of Alcoholism Robert Hitzemann, Ph.D. Departments of Behavioral Neuroscience & Psychiatry Oregon Health & Science University Genetics, Genomics and Alcoholism Robert Hitzemann, Ph.D. Departments

MOLECULAR SERVICES. mlabs.umich.edu

MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service

Autism genetics: searching for specificity and convergence

R E V I E W Autism genetics: searching for specificity and convergence Jamee M Berg 1,2,3 and Daniel H Geschwind 2,3,4 * Abstract Advances in genetics and genomics have improved our understanding of autism

Clinical Laboratory Fee Schedule CY 2015 Updates June 9, 2014

Clinical Laboratory Fee Schedule CY 2015 Updates June 9, 2014 Please note that this listing includes the most recent codes provided by the American Medical Association (AMA), and that it is subject to

Improving molecular diagnosis in epilepsy by a dedicated high-throughput

1" 2" Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform 3" 4" 5" 6" 7" 8" Authors: Erika Della Mina 1, Roberto Ciccone 1, Francesca Brustia 2, Baran Bayindir

The Amazing Brain Webinar Series: Select Topics in Neuroscience and Child Development for the Clinician

The Amazing Brain Webinar Series: Select Topics in Neuroscience and Child Development for the Clinician Part VII Recent Advances in the Genetics of Autism Spectrum Disorders Abha R. Gupta, MD, PhD Jointly

Annotation SNPEff_ Annotation SNPEff_. SNPEff_. Annotation. SNPEff_. Annotation. SNPEff_. Annotation. SNPEff_. Annotation

Chr Gene p-value Binned_ variants Phenotype Biological_Feature Note 11 DRD2 0.001179727 35 Asthma Gene 16 CES2 0.010970381 40 Asthma Gene 19 LDLR 0.023074213 43 Asthma Gene 10 ARID5B 0.025870289 44 Asthma

X inactivation enables Dosage Compensation in mammals H. J. Muller first proposed the concept of dosage compensation as a result of his studies on the expression of X-linked genes in Drosophila. Muller,

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial

Whole exome sequencing Gene package Epilepsy version 2,

Whole Exome Sequencing Gene package Epilepsy, version 2, 1 7 2017 Technical information After DNA was enriched using Agilent Sureselect Clinical Research Exome (CRE) Capture, samples were run on the Illumina

Epi4K. Epi4K Consortium. Epi4K: gene discovery in 4,000 genomes, Epilepsia, 2012 Aug;53(8):

Epi4K Epi4K Consortium. Epi4K: gene discovery in 4,000 genomes, Epilepsia, 2012 Aug;53(8):1457-67. Genetics of Epileptic Encephalopathies Infantile Spasms (IS) 1 in 3000 live births and onset between 4-12

The Institute of Neurological Sciences, VHS Multispecialty Hospital and Research Institute, RG Salai, Taramani Chennai Tamil Nadu, India

69 The Social Brain Network and Autism Vivek Misra The Institute of Neurological Sciences, VHS Multispecialty Hospital and Research Institute, RG Salai, Taramani Chennai 600113 Tamil Nadu, India Abstract

Exons from 137 genes were targeted for hybrid selection and massively parallel sequencing.

SUPPLEMENTARY TABLES Supplementary Table 1. Targeted Genes ABL1 ABL2 AKT1 AKT2 AKT3 ALK APC ATM AURKA BCL2 BRAF BRCA1 BRCA2 CCND1 CCNE1 CDC73 CDH1 CDK4 CDK6 CDK8 CDKN1A CDKN2A CEBPA CHEK1 CHEK2 CREBBP

Cytogenetic Biochemical

Diagnostic Laboratories Test Menu Molecular Cytogenetic Biochemical Table of Contents Lab Directors & Genetic Counselors...2 Molecular Diagnostic Lab Next Generation Sequencing Panels...3 Biochemical Diagnostic

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic

Jocelyn Chapman, MD Division of Gynecologic Oncology Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic Genetics underlies all cancers Somatic or tumor genetics Germline or inherited genetics

The Center for PERSONALIZED DIAGNOSTICS

The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)

Autism/ID Xpanded Panel Gene List (~2000)

Autism/ID Xpanded Panel Gene List (~2000) Approximately 84% of the genes are covered >99% at 10X and the average coverage of a gene at 10X for this panel is >98%. A2M A2ML1 AAAS AARS AARS2 AASS ABAT ABCA1

Novel mutation of type 1 insulin-like growth factor receptor (IGF1R) gene in a severe short stature pedigree identified by targeted

Research Article Novel mutation of type 1 insulin-like growth factor receptor (IGF1R) gene in a severe short stature pedigree identified by targeted next-generation sequencing Running title: Novel mutation

MLPA SAMPLES USER GUIDE

MLPA SAMPLES USER GUIDE MLPA microdeletion studies Requirements: 1-2 mls (minimum) of peripheral blood in a lithium heparin tube (green or orange top) AND 1-2 mls of peripheral blood in a EDTA tube (purple

Supplementary Table 1. Information on the 174 single nucleotide variants identified by whole-exome sequencing

Supplementary Table 1. Information on the 174 single nucleotide s identified by whole-exome sequencing Chr Position Type AF exomes Database 1 10163148 A/G UBE4B missense 0.000326 1534 2 98 1 4.44 Damaging

Pol Andrés Benito 1, Jesús Moreno 1, Ester Aso 1, Mónica Povedano 2 1, 3, 4, 5. , Isidro Ferrer. Research Paper ABSTRACT INTRODUCTION

dominant but also recessive and X-linked in some families. However, about 13% of sals cases bear a gene mutation linked to fals. Main pathological features in sals are loss of myelin and axons in the pyramidal

# DISEASE GENE GHI CHÚ 1 17-beta-hydroxysteroid dehydrogenase defciency, type HSD17B Hydroxy-3-methylglutaryl-CoA lyase deficiency HMGCL

# DISEASE GENE GHI CHÚ 1 17-beta-hydroxysteroid dehydrogenase defciency, type HSD17B3 III 2 3-Hydroxy-3-methylglutaryl-CoA lyase HMGCL 3 3-hydroxyacyl-CoA dehydrogenase defciency HADH 4 3-hydroxyisobutryl-CoA

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Prices listed correspond to institutional rates only; please contact the lab for insurance rates. Genetic Test Neurofibromatosis Type 1 - NF1 and Legius syndrome SPRED1 $1400 (NF1/SPRED1 negative) 81408,

Table of Contents. Preface Abstract Acknowledgements... 9

Table of Contents Preface... 5 Abstract... 7 Acknowledgements... 9 1. Introduction... 17 1.1 Bipolar Affective Disorder... 17 1.1.1 History and Symptomatology of Bipolar Disorder... 17 1.1.2 Pharmacotherapy...

Table e-1: Investigation of 33 patients with early onset epilepsy for KCNT1 mutations.

Table e1: Investigation of 33 patients with early onset epilepsy for KCNT1 mutations. Patient Phenotype Screening Method Diagnostic Karyotype Sanger sequencing NGS Diagnostic Panel WES chromosomal microarray

Leistungsverzeichnis

Leistungsverzeichnis SYNLAB MVZ Humangenetik Mannheim Genetische Beratung / Molekulargenetische Diagnostik / Molekulare Zytogenetik / Abstammungsgutachten und Vaterschaftstest www.zhma.de Akkreditiert

Identification by genetics of. expressed in the brain as potential novel

Identification by genetics of neurotransmitter and other transporters expressed in the brain as potential novel targets for schizophrenia 13 rd November 2014, Drug Transporters symposium, target of avoid?

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Prices listed correspond to institutional rates only; please contact the lab for insurance rates. Genetic Test Neurofibromatosis Type 1 - NF1 and Legius syndrome SPRED1 $1400 (NF1/SPRED1 negative) 81408,

SNP Microarray. Prenatal Disorder List

SM SNP Microarray Prenatal Disorder List Revealing Answers to Complex Questions Reveal SM SNP Microarray is a high density copy number array that can also detect copy neutral changes such as uniparental

Whole exome sequencing Gene package Epilepsy version 3,

Whole Exome Sequencing Gene package Epilepsy, version 3, 1 2 2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired end sequenced on the Illumina

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS NF1/SPRED1 and Other RASopathy Related Conditions on Blood/Saliva NF1- only NGS testing and copy number analysis for

De novo variants in neurodevelopmental disorders with epilepsy

SUPPLEMENTARY INFORMATION Analysis https://doi.org/10.1038/s41588-018-0143-7 In the format provided by the authors and unedited. De novo variants in neurodevelopmental disorders with epilepsy Henrike O.

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Frampton et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Supplementary Figure 1A Base substitution detection

Table S1. Demographics of patients and tumor characteristics.

Supplemental Tables for: A Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers Kim Hirshfield et al. Table S1. Demographics of patients and tumor characteristics.

Lions and Tigers and Bears.Oh My!

Lions and Tigers and Bears.Oh My! TAKING THE FEAR OUT OF GENETIC TESTING Lisa Butterfield, MS, CGC Genetic Counselor Clinical Assistant Professor University of Kansas Health System Why is Genetic Testing

Provide your cancer patients personalized treatment options with ClariFind

ONCOLOGY ClariFind employs next-generation sequencing (NGS) for comprehensive genomic profiling of a patient s tumor sample to identify potential clinically actionable targets and associated therapies.

The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements

Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 8 1.5. Primary Tumour Description... 10 1.6.

Illumina Clinical Services Laboratory

Illumina Clinical Services Laboratory CLIA Certificate No.: 05D1092911 Illumina Clinical Services Laboratory TruGenome Predisposition Screen Requisition Form The TruGenome Predisposition Screen is intended

Why Pathway/Network Analysis?

6/8/16 More Depth on Pathway and Network Analysis Lincoln Stein Why Pathway/Network Analysis? Drama@c data size reduc@on: 1000 s of genes => dozens of pathways. Increase sta@s@cal power by reducing mul@ple

SUPPORTING INFORMATION

SUPPORTING INFORMATION SUPPORTING METHODS... 2 SUPPORTING FIGURES... 3 Figure S1. Decisional trees for the molecular diagnosis of intellectual disability.... 3 Figure S2. DYRK1A, two de novo truncating

UKGTN Testing Criteria

Test name: Epilepsy 53 Gene Panel UKGTN Testing Criteria Approved name and symbol of disorder/condition(s): Epilepsy Panel Test See Appendix 1 Approved name and symbol of gene(s): See Appendix 2 OMIM number(s):

SUPPLEMENTARY INFORMATION

Table S1. Neuropsychiatric risk loci with a reported effect on structural plasticity Gene or copy number variant Gene name or description Type of effect on spines and/or dendrites Disease associations

Rebecca Muhle, M.D. Ph.D. Yale Child Study Center Yale University The Autism Center Hospital for Special Care

Genetic Work-Up of Autism Spectrum Disorder in a Clinical Setting Rebecca Muhle, M.D. Ph.D. Yale Child Study Center Yale University The Autism Center Hospital for Special Care Disclosures statement I have

Hepatocellular Carcinoma (HCC): What Treatment Modality for Which Tumor?

K. Rajender Reddy, MD, CG Hepatocellular Carcinoma (HCC): What Treatment Modality for Which Tumor? K. Rajender Reddy, MD, CG Ruimy Family President s Distinguished Professor of Medicine Director of Hepatology